kalkinemedia4m
New Era in Schizophrenia Care with Bristol Myers Squibb's COBENFY Approval
Highlights,Bristol Myers Squibb's shares rose following the FDA's approval of COBENFY, the first new schizophrenia treatment ...
The Globe and Mail4m
Dow Jones Climbs to New Record Highs, While the Nasdaq Slides
Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...
MM&M57m
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Cobenfy approval draws optimism from Street, though with caveats
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
mashviral2h
New Schizophrenia Drug Gets FDA Green Light — First of Its Kind in Over 30 years
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
Top Stock Movers Now: Wynn Resorts, AT&T, Newmont, and More
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
btimesonline2h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
New Drug For Schizophrenics Has Experts Excited
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
SchaeffersResearch.com3h
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
The American Journal of Managed Care3h
First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...